Canopy Growth (NYSE:CGC) and Entia Biosciences (OTCMKTS:ERGO) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, risk, dividends, earnings, analyst recommendations, institutional ownership and profitability.
This table compares Canopy Growth and Entia Biosciences’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This is a breakdown of recent recommendations and price targets for Canopy Growth and Entia Biosciences, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Canopy Growth presently has a consensus price target of $61.00, suggesting a potential upside of 132.65%. Given Canopy Growth’s higher probable upside, equities research analysts clearly believe Canopy Growth is more favorable than Entia Biosciences.
Earnings & Valuation
This table compares Canopy Growth and Entia Biosciences’ gross revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Canopy Growth||$60.79 million||100.14||-$54.88 million||($0.32)||-81.94|
|Entia Biosciences||$260,000.00||1.31||-$1.39 million||N/A||N/A|
Entia Biosciences has lower revenue, but higher earnings than Canopy Growth.
Institutional and Insider Ownership
12.0% of Canopy Growth shares are held by institutional investors. 28.3% of Entia Biosciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Risk & Volatility
Canopy Growth has a beta of 3.55, suggesting that its share price is 255% more volatile than the S&P 500. Comparatively, Entia Biosciences has a beta of 4.9, suggesting that its share price is 390% more volatile than the S&P 500.
Entia Biosciences beats Canopy Growth on 6 of the 11 factors compared between the two stocks.
About Canopy Growth
Canopy Growth Corporation, together with its subsidiaries, engages in growing, possession, and sale of medical cannabis in Canada. Its products include dried flowers, oils and concentrates, softgel capsules, and hemps. The company offers its products under the Tweed, Black Label, Spectrum Cannabis, DNA Genetics, Leafs By Snoop, Bedrocan Canada, CraftGrow, and Foria brand names. It also offers its products through Tweed Main Street, a single online platform that enables registered patients to purchase medicinal cannabis from various producers across various brands. The company was formerly known as Tweed Marijuana Inc. and changed its name to Canopy Growth Corporation in September 2015. Canopy Growth Corporation is headquartered in Smiths Falls, Canada.
About Entia Biosciences
Entia Biosciences, Inc. engages in the development, production, and distribution of dietary supplements, nutraceuticals, and medical foods products in the United States. It is also involved in the discovery, scientific evaluation, and marketing of natural formulations that can be used in medical foods, nutraceuticals, cosmetics, and other products. The company’s portfolio of formulations include ErgoD2, a pharmaceutical grade organic compound from whole food that contains the micro-nutrients; L-Ergothioneine, a naturally occurring amino acid and master antioxidant; and vitamin D, an antioxidant. In addition, it is also developing products for the chronic kidney disease and other diseases, as well as providing cosmeceuticals and other beauty products under the GROH brand name. Entia Biosciences, Inc. offers its products directly to consumers through e-commerce channels, such as direct email marketing, social media outlets, and e-commerce sites. The company was formerly known as Total Nutraceutical Solutions, Inc. and changed its name to Entia Biosciences, Inc. in January 2012. Entia Biosciences, Inc. was founded in 2007 and is headquartered in Sherwood, Oregon.
Receive News & Ratings for Canopy Growth Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Canopy Growth and related companies with MarketBeat.com’s FREE daily email newsletter.